This observation provides a useful comparator to Case 5 in our study, in which the patient had PPI-induced hypomagnesemia and was treated with empagliflozin, a selective SGLT2 inhibitor with minimal SGLT1 inhibition. This evidence concerns the gene SLC5A1 and familial primary hypomagnesemia.